Introduction
Viral infections represent a well-known complication in children receiving hemopoietic stem cell transplant (HSCT). Their epidemiology is related to the type of HSCT donor (autologous vs allogeneic), the immune status of the donor and/or the recipient, and the time elapsed from the HSCT. 1, 2 Overall, viral infections are a rare event after autologous HSCT, while many viruses have been demonstrated to cause disease in allogeneic HSCT recipients. However, some viral diseases may have been considered 'rare' until recently because of the absence of diagnostic tools that led to many clinical pictures being undiagnosed (for example, human meta-pneumovirus (hMPV), pneumonia). 3 Viral diseases may frequently represent the reactivation of a latent infection, 3 but primary viral infections are also a possible feature, especially in children. 4, 5 In this case, healthy household contacts and health-care workers may represent an important source of the disease. Moreover, it must be kept in mind that in some cases the clinical picture in adults may be different from that observed in children (for example, respiratory syncytial virus may cause an upper respiratory tract disease in adults and bronchiolitis in infants) and that any infectious disease is generally more severe in immunocompromised patients. All these aspects should be considered for the development of infectious diseases prevention strategies.
In the following paragraphs, we will briefly describe some features of rare viral diseases occurring after HSCT in children. Table 1 summarizes the different clinical pictures associated with viral infections according to the type of HSCT.
Autologous HSCT
Viral infections are generally rare after autologous HSCT. The most frequent is probably herpes simplex virus reactivation during pre-engraftment stomatitis, 6 while CMV has been reported as the cause of severe infection in no more than 3% of patients, mainly because of primary infection. 7 Rotavirus and adenovirus have been reported as a cause of clinically relevant dehydration, metabolic acidosis, mucositis and neutropenia in cancer patients, including autologous HSCT recipients, 8 and many pediatric cases seem to be nosocomial in origin. 9, 10 Norovirus, another important cause of gastroenteritis in hospitalized children, 11 caused an outbreak in a pediatric oncology unit, with some patients experiencing severe or life-threatening diseases, 12 but at present no case in HSCT recipients has been reported. Viral gastroenteritis may represent an important cause of mucous damage (other than chemotherapy-induced mucositis) that may cause the penetration of enteric bacteria into the bloodstream. 13 Therefore, HSCT recipients with viral enteritis must be followed very carefully, especially in the presence of concomitant neutropenia, and every effort must be made to prevent the diffusion of these infections to other patients admitted in the same Unit. Therefore, since the shedding of these viruses may be prolonged, 9, 12 during the acute phase of the illness, health-care workers should wear masks in addition to practicing meticulous hand hygiene with a disinfectant of proven activity against viruses.
Other viruses, such as human herpesvirus-6 (HHV-6) and HHV-7, have been detected in the blood of autologous HSCT recipients, but their pathogenic role in these settings is unclear. [14] [15] [16] Finally, the incidence of respiratory syncytial virus pneumonia has been reported to be 1.5% in adults or adolescents undergoing autologous HSCT. 17 No data in younger children are available.
Allogeneic HSCT
Viral infections represent a frequent complication in HSCT recipients, especially those receiving transplant from an alternative donor. 1, 2 HHV-6 and HHV-7 have been frequently detected in the blood of allogeneic HSCT recipients. Prolonged HHV-6 reactivation has been associated with fever, rash, delayed engraftment and encephalitis, and in this case viral DNA has been detected in the cerebrospinal fluid by PCR. 14, 18 Also, HHV-7 has been reported as a cause of severe central nervous system disease after allogeneic HSCT. 16, 19 Moreover, HHV-7 was associated with severe GvHD and sepsis secondary to severe immunosuppression after HSCT from matched unrelated donors. 20 HHV-8 has been associated with the development of visceral Kaposi's sarcoma or lymphomas in immunocompromised patients, [21] [22] [23] and de Medeiros et al. 24 have reported a case of Kaposi's sarcoma after allogeneic HSCT. However, a survey on the presence of serum HHV-8 DNA after bone marrow transplantation performed in 187 Italian HSCT donor-recipient pairs did not show any HHV-8-related complications after a median of 6 years of follow-up. 25 BK virus is the main cause of hemorrhagic cystitis after allogeneic HSCT, 3, 26 especially in the presence of GvHD. 27 However, it must be remembered that CMV and adenovirus 28 also have been associated with the development of hemorrhagic cystitis, sometimes in association with BK virus. [28] [29] [30] [31] [32] Among the papovavirus family, JC virus has been reported as a cause of multifocal leukoencephalopathy in cancer patients receiving chemotherapy and rituximab, in one case combined with autologous HSCT. 33, 34 Parvovirus B19 has been reported to cause persistent infection (several months or years) in immunocompromised hosts mainly due to impairment of B-cell function. 35, 36 This infection is associated with viremia and may result in pure red cell aplasia or pancytopenia, also in allogeneic HSCT recipients. 37, 38 In this case, the quantitative determination of B19 DNA correlated inversely with the reticulocyte count. 38 Recently, infection with hMPV has been associated with the presence of hemorrhagic pneumonia after HSCT. 39 However, the same virus has also been detected in 21 asymptomatic patients. 40 Therefore, at present, the real pathogenic role of hMPV in allogeneic HSCT recipients is still unclear.
Rotavirus and norovirus may also represent important causes of gastroenteritis after allogeneic HSCT, but data are scarce. 8, 12 On the contrary, adenovirus represents a well-known cause of disease (gastroenteritis, hepatitis and disseminated diseases have been described), especially in children. 3 In any case, strict isolation of patients with viral gastroenteritis is mandatory for decreasing the risk of epidemic diffusion within HSCT units. 
Hepatitis viruses in autologous and allogeneic HSCT
The last paragraph must be reserved for hepatitis viruses, which may cause liver damage in both autologous and allogeneic HSCT.
At present, hepatitis B virus (HBV) and hepatitis C virus (HCV) could not represent an important cause of disease in children receiving HSCT in developed countries, but they may be an important problem for patients living in endemic areas (for HBV) and/or in the presence of inadequate pretransfusion blood screening (both HBV and HCV). These aspects must be kept in mind in developed countries, especially in an era of increasing health-care immigration.
The presence of HBV or HCV infection is a matter of concern for its consequences both early after BMT and for long-term survivors. 41 In a retrospective study on liver disease in HBV-or HCV-positive patients undergoing allogeneic HSCT or in negative patients who received transplant from positive donors, liver disease represented an important cause of morbidity and mortality 42 during a relatively short-term follow-up (median 24 months). In this survey, 13% of the patients presented severe liver disease, with a 47% of fulminant hepatitis and 29% of venoocclusive disease. Reverse seroconversion of HBV is not a rare complication in autologous HSCT, 43 and in allogeneic HSCT recipients the risk seems to be higher during the tapering of the immunosuppressive therapy. 42 Moreover, in this setting, fulminant hepatitis due to HCV 44, 45 or HBV 46 has been described. Therefore, even if infection with hepatotropic viruses does not represent a major contraindication for HSCT, 47 a careful follow-up is recommendable, especially during immunosuppression tapering. 42 As regards the risk of severe long-term liver disease, data from adults did not show differences in the incidence of severe liver diseases between autologous and allogeneic HSCT. 47 Moreover, a recent survey on 17 children who underwent very long follow-up (range 10-18.5 years) did not show the development of hepatic failure, cirrhosis or hepatocarcinoma, even in the presence of active hepatic cytolysis through the follow-up. 48 Finally, as regards infections due to 'other' hepatitis viruses, no data are available on HAV acute hepatitis after HSCT, while infection with HGV has been reported in HSCT recipients. [49] [50] [51] The data available in the pediatric population do not support any pathogenic role after either chemotherapy 52 or HSCT. 41 
